Bevasiranib clinical trials
How each study uses bevasiranib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2004 (1)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses bevasiranib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)WithdrawnPhase 3OPKO Health, Inc.NCT00557791Written as Bevasiranib
- Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMDTerminatedPhase 3OPKO Health, Inc.NCT00499590Written as bevasiranib
- Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular DegenerationCompletedPhase 2OPKO Health, Inc.NCT00259753Written as Bevasiranib
- Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular EdemaCompletedPhase 2OPKO Health, Inc.NCT00306904Written as bevasiranib
- Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5CompletedPhase 1OPKO Health, Inc.NCT00722384Written as bevasiranib
Codes
What other systems call bevasiranib · ClinicalTrials.gg INT005746
- MeSH (NLM) C554088bevasiranibOne source NLM
- UNII (FDA) DGN36694W4BEVASIRANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q851528bevasiranibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169809BevasiranibOne source FDA
- DrugBank DB06642One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C554088 | bevasiranib | One source NLM |
| UNII (FDA) | DGN36694W4 | BEVASIRANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q851528 | bevasiranib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169809 | Bevasiranib | One source FDA |
| DrugBank | DB06642 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.